[144] Factset Research Systems SEC Filing

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) filed a Form 6-K with the SEC dated 14 July 2025. The filing furnishes a press release titled “CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations.” No financial statements, earnings metrics or transactional details accompany the submission. The press release is attached as Exhibit 99.1 and incorporated by reference. The report was signed by Deputy CEO and CFO Eran Rotem.

The document discloses an executive appointment intended to bolster CollPlant’s commercial presence in North America but contains no quantitative guidance or other material financial information.

Insights

Financial Analyst

TL;DR: Routine 6-K discloses a leadership hire; negligible immediate financial impact.

The current report simply furnishes a press release announcing the appointment of a new Head of North America Commercial Operations. The absence of financial figures, strategic metrics or guidance renders the filing largely informational. While adding an experienced collagen biomaterials professional could support future U.S. commercialization, investors lack details to gauge revenue impact or timing. Accordingly, the disclosure is neutral from a valuation standpoint and unlikely to influence near-term market perception.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Citigroup Global Markets Inc 390 Greenwich St New York NY 10013	2925	1319994.00	37806774	07/14/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	07/14/2025	Stock option exercise and sale	FACTSET RESEARCH SYSTEMS INC.			2925	07/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did CollPlant (CLGN) report in its July 14 2025 Form 6-K?

CollPlant furnished a press release announcing the appointment of a collagen biomaterials expert as Head of North America Commercial Operations.

Does the 6-K include any financial results or guidance?

No. The filing contains no financial statements, earnings data or forward-looking guidance.

Who signed the Form 6-K for CollPlant?

Deputy CEO and Chief Financial Officer Eran Rotem signed the report.

Which exhibit accompanies the Form 6-K filing?

Exhibit 99.1 is the full press release dated July 14 2025.